Recent Advances on Pt-Based Compounds for Theranostic Applications
Molecules · 2024
DOI: 10.3390/molecules29153453 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2024. Verfasst von Giulia Ferrari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Maynooth University, W23 F2H6 Maynooth, Ireland. Hauptthemen laut MEDLINE: Theranostic Nanomedicine, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON-MSCA-2021-DN-01, STRIKE project HORIZON-MSCA-2021-DN-01.
Abstract (Originalsprache)
Since the discovery of cisplatin’s antitumoral activity and its approval as an anticancer drug, significant efforts have been made to enhance its physiological stability and anticancer efficacy and to reduce its side effects. With the rapid development of targeted and personalized therapies, and the promising theranostic approach, platinum drugs have found new opportunities in more sophisticated systems. Theranostic agents combine diagnostic and therapeutic moieties in one scaffold, enabling simultaneous disease monitoring, therapy delivery, response tracking, and treatment efficacy evaluation. In these systems, the platinum core serves as the therapeutic agent, while the functionalized ligand provides diagnostic tools using various imaging techniques. This review aims to highlight the significant role of platinum–based complexes in theranostic applications, and, to the best of our knowledge, this is the first focused contribution on this type of platinum compounds. This review presents a brief introduction to the development of platinum chemotherapeutic drugs, their limitations, and resistance mechanisms. It then describes recent advancements in integrating platinum complexes with diagnostic agents for both tumor treatment and monitoring. The main body is organized into three categories based on imaging techniques: fluorescence, positron emission tomography (PET), single–photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Finally, this review outlines promising strategies and future perspectives in this evolving field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Maynooth University, W23 F2H6 Maynooth, Ireland.
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.
- Preclinical Imaging Lab (PIL), Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.
- Medical Imaging Cluster (MIC), Medical University of Vienna, 1090 Vienna, Austria.
- Kathleen Londsdale Institute for Human Health Research, Maynooth University, W23 F2H6 Maynooth, Ireland.
ORCID-Profile: Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
Förderung
- HORIZON-MSCA-2021-DN-01
- STRIKE project HORIZON-MSCA-2021-DN-01
Zitieren
APA
Ferrari, G., Lopez-Martinez, I., Wanek, T., Kuntner, C., & Montagner, D. (2024). Recent Advances on Pt-Based Compounds for Theranostic Applications. Molecules. https://doi.org/10.3390/molecules29153453
Vancouver
Ferrari G, Lopez-Martinez I, Wanek T, Kuntner C, Montagner D. Recent Advances on Pt-Based Compounds for Theranostic Applications. Molecules. 2024. doi:10.3390/molecules29153453
BibTeX
@article{Ferrari2024,
author = {Ferrari, Giulia and Lopez-Martinez, Ines and Wanek, Thomas and Kuntner, Claudia and Montagner, Diego},
title = {Recent Advances on Pt-Based Compounds for Theranostic Applications},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29153453}
}
EUVIMED